Molecular characterization of the intestinal microbiota in patients with and without abdominal bloating

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 310, Issue 6, 2016, Pages G417-G426

  Kulka, Tamar Ringel ^a   Benson, Andrew K ^b   Carroll, Ian M ^c   Kim, Jaehyoung ^b   Legge, Ryan M ^b   Ringel, Yehuda ^c  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

16S rRNA gene; Abdominal bloating; Intestinal microbiota; Irritable bowel syndrome; Pyrosequencing

Indexed keywords

RNA 16S; BACTERIAL DNA;

ACTINOMYCES; ADULT; ARTICLE; BLOATING; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FECES; FECES ANALYSIS; FEMALE; GASTROINTESTINAL SYMPTOM; GENE; HUMAN; INTESTINAL DYSMOTILITY; INTESTINE FLORA; IRRITABLE COLON; LACHNOSPIRACEAE; LACTOBACILLUS; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PYROSEQUENCING; STREPTOCOCCUS THERMOPHILUS; TAXON; ABDOMINAL CAVITY; BIOSYNTHESIS; CHEMISTRY; COHORT ANALYSIS; GENETICS; INTESTINE; LESIONS AND DEFECTS; MICROBIOLOGY; MICROFLORA; MIDDLE AGED; PATHOPHYSIOLOGY; YOUNG ADULT;

ABDOMINAL CAVITY; ADULT; COHORT STUDIES; DILATATION, PATHOLOGIC; DNA, BACTERIAL; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; INTESTINES; IRRITABLE BOWEL SYNDROME; MALE; MICROBIOTA; MIDDLE AGED; RNA, RIBOSOMAL, 16S; YOUNG ADULT;

EID: 84983784751     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00044.2015     Document Type: Article

References (36)

1. Benson AK, Kelly SA, Legge R, Ma F, Low SJ, Kim J, Zhang M, Oh PL, Nehrenberg D, Hua K, Kachman SD, Moriyama EN, Walter J, Peterson DA, Pomp D. Individuality in gut microbiota composition is a complex polygenic trait shaped by multiple environmental and host genetic factors. Proc Natl Acad Sci USA 107: 18933–18938, 2010.
2. Carroll IM, Chang YH, Park J, Sartor RB, Ringel Y. Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Gut Pathog 2: 19, 2010.
3. Carroll IM, Ringel-Kulka T, Keku TO, Chang YH, Packey CD, Sartor RB, Ringel Y. Molecular analysis of the luminal- and mucosalassociated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 301: G799–G807, 2011.
4. Carroll IM, Ringel-Kulka T, Siddle JP, Klaenhammer TR, Ringel Y. Characterization of the fecal microbiota using highthroughput sequencing reveals a stable microbial community during storage. PLoS One 7: E46953, 2012.
5. Carroll IM, Ringel-Kulka T, Siddle JP, Ringel Y. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterology 24: 521–530, e248, 2012.
6. Faith JJ, Guruge JL, Charbonneau M, Subramanian S, Seedorf H, Goodman AL, Clemente JC, Knight R, Heath AC, Leibel RL, Rosenbaum M, Gordon JI. The long-term stability of the human gut microbiota. Science 341: 1237439, 2013.
7. Jeffery IB, O’Toole PW, Öhman L, Claesson MJ, Deane J, Quigley EM, Simrén M. An irritable bowel syndrome subtype defined by speciesspecific alterations in faecal microbiota. Gut 61: 997–1006, 2012.
8. Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thomforde GM, Zinsmeister AR. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 17: 895–904, 2003.
9. King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 352: 1187–1189, 1998.
10. Knights D, Silverberg MS, Weersma RK, Gevers D, Dijkstra G, Huang H, Tyler AD, van Sommeren S, Imhann F, Stempak JM, Huang H, Vangay P, Al-Ghalith GA, Russell C, Sauk J, Knight J, Daly MJ, Huttenhower C, Xavier RJ. Complex host genetics influence the microbiome in inflammatory bowel disease. Genome Med 6: 107, 2014.
11. Leamy LJ, Kelly SA, Nietfeldt J, Legge RM, Ma F, Hua K, Sinha R, Peterson DA, Walter J, Benson AK, Pomp D. Host genetics and diet, but not immunoglobulin A expression, converge to shape compositional features of the gut microbiome in an advanced intercross population of mice. Genome Biol 15: 552, 2014.
12. Li W, Godzik A. CD-HIT: a fast program for clustering and comparing large sets of protein or nucleotide sequences. Bioinformatics 22: 1658–1659, 2006.
13. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 130: 1480–1491, 2006.
14. Lyra A, Rinttilä T, Nikkilä J, Krogius-Kurikka L, Kajander K, Malinen E, Mättö J, Mäkelä L, Palva A. Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification. World J Gastroenterol 15: 5936–5945, 2009.
15. Malinen E, Krogius-Kurikka L, Lyra A, Nikkilä J, Jääskeläinen A, Rinttilä T, Vilpponen-Salmela T, von Wright AJ, Palva A. Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome. World J Gastroenterol 16: 4532–4540, 2010.
16. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J 2: 653–654, 1978.
17. Maxton DG, Martin DF, Whorwell PJ, Godfrey M. Abdominal distension in female patients with irritable bowel syndrome: exploration of possible mechanisms. Gut 32: 662–664, 1991.
18. McKnite AM, Perez-Munoz ME, Lu L, Williams EG, Brewer S, Andreux PA, Bastiaansen JWM, Wang X, Kachman SD, Auwerx J, Williams RW, Benson AK, Peterson DA, Ciobanu DC. Murine gut microbiota is defined by host genetics and modulates variation of metabolic traits. PLoS One 7: e39191, 2012.
19. Ong DK, Mitchell SB, Barrett JS, Shepherd SJ, Irving PM, Biesiekierski JR, Smith S, Gibson PR, Muir JG. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol 25: 1366–1373, 2010.
20. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 364: 22–32, 2011.
21. Pruesse E, Quast C, Knittel K, Fuchs BM, Ludwig W, Peplies J, Glöckner FO. SILVA: a comprehensive online resource for quality checked and aligned ribosomal RNA sequence data compatible with ARB. Nucleic Acids Res 35: 7188–7196, 2007.
22. Rajilić-Stojanović M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, de Vos WM. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 141: 1792–1801, 2011.
23. Rigsbee L, Agans R, Shankar V, Kenche H, Khamis HJ, Michail S, Paliy O. Quantitative profiling of gut microbiota of children with diarrheapredominant irritable bowel syndrome. Am J Gastroenterol 107: 1740–1751, 2012.
24. Ringel Y, Carroll IM. Alterations in the intestinal microbiota and functional bowel symptoms. Gastrointest Endosc Clin N Am 19: 141–150, 2009.
25. Ringel Y, Williams RE, Kalilani L, Cook SF. The prevalence, characteristics and impact of bloating symptoms in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 7: 68–72, 2009.
26. Ringel-Kulka T, Palsson OS, Maier D, Carroll I, Galanko JA, Leyer G, Ringel Y. Clinical trial: Probiotic bacteria lactobacillus acidophilus NCFM and bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study. J Clin Gastroenterol 45: 518–525, 2011.
27. Salonen A, de Vos WM, Palva A. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. Microbiology 156: 3205–3215, 2010.
28. Saulnier DM, Riehle K, Mistretta TA, Diaz MA, Mandal D, Raza S, Weidler EM, Qin X, Coarfa C, Milosavljevic A, Petrosino JF, Highlander S, Gibbs R, Lynch SV, Shulman RJ, Versalovic J. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology 141: 1782–1791, 2011.
29. Saulnier DM, Ringel Y, Heyman MB, Foster JA, Bercik P, Shulman RJ, Versalovic J, Verdu EF, Dinan TG, Hecht G, Guarner F. The intestinal microbiome, probiotics and prebiotics in neurogastroenterology. Gut Microbes 4: 17–27, 2013.
30. Serra J, Azpiroz F, Malagelada JR. Mechanisms of intestinal gas retention in humans: impaired propulsion versus obstructed evacuation. Am J Physiol Gastrointest Liver Physiol 281: G138–G143, 2001.
31. Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, El Hajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 101: 333, 2006.
32. Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: The effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 29: 508–518, 2009.
33. Simren M, Barbara G, Flint H, Spiegel BM, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG; Rome Foundation Committee. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 62: 159–176, 2013.
34. Srinivas S, Möller S, Wang J, Künzel S, Zillikens D, Baines JF, Ibrahim SM. Genome-wide mapping of gene-microbiota interactions in susceptibility to autoimmune skin blistering. Nat Commun 4: 2462, 2013.
35. Staudacher HM, Whelan K, Irving PM, Lomer MC. Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. J Hum Nutr Diet 24: 487–495, 2011.
36. Wang Q, Garrity G, Tiedje J, Cole J. Naive bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol 73: 5261–5267, 2007.